Can patients with hematological cancers continue to use selinesol/silvio?

Selinexor is a drug used to treat multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). It is a selective nuclear export inhibitor (SINE) that changes protein transport in tumor cells by inhibiting XPO1 protein (nuclear export protein), ultimately leading to tumor cell death. Selinisol has shown certain clinical efficacy, especially in the treatment of blood tumors such as multiple myeloma.

1. Long-term and continuous treatment

For patients with hematologic malignancies, long-term use of selinesol depends on the patient's condition, response to treatment, and drug tolerance. Many patients may benefit from initial treatment with selinesol, especially when other treatments have failed. However, long-term use of the drug usually needs to be assessed on a patient-specific basis. Patients with hematological malignancies may experience fluctuations in their condition during treatment, and some patients may have to adjust or stop using selinesol due to side effects, drug resistance, or other complications.

2. Drug resistance and efficacy evaluation

Selinesol use may lead to drug resistance, especially with long-term treatment. The patient's condition may see the effects of treatment diminish after a certain period of time, so regular monitoring of efficacy and side effects is required to ensure the continued effectiveness of treatment. As the condition changes, the doctor may adjust the treatment plan based on the patient's response, which may include increasing the dose of the drug, changing the drug, or combining it with other treatments.

3. Side effects and adjustments in treatment

Side effects of selinesol include nausea, loss of appetite, fatigue, and leukopenia, which may become more pronounced with long-term use. Therefore, when doctors use selinesol for patients with hematological tumors, they will make individual adjustments based on the patient's response and decide whether to continue using the drug based on the occurrence of side effects. If side effects are severe, it may be recommended to suspend treatment or change your treatment plan.

Keyword tags: selinesol, Multiple myeloma, diffuse large B-cell lymphoma, hematological neoplasms, nuclear export inhibitors, drug resistance, treatment response, quality of life, side effects

Reference materials:https://go.drugbank.com/drugs/DB11942